Table 3. Adverse events documented during IO.
| Adverse event | Overall, n (%) | No peripheral eosinophilia during treatment, n (%) | Peripheral eosinophilia during treatment, n (%) | P value |
|---|---|---|---|---|
| Asthenia (all grades) | 27 (22.3) | 15 (17.0) | 12 (36.4) | 0.023 |
| Grade 3–5 | 2 (7.4) | 0 | 2 (16.7) | |
| Hypothyroidism (all grades) | 8 (6.6) | 4 (4.5) | 4 (12.1) | 0.212 |
| Grade 3–5 | 0 | 0 | 0 | |
| Pneumonitis (all grades) | 8 (6.6) | 5 (5.7) | 3 (9.1) | 0.682 |
| Grade 3–5 | 4 (50.0) | 3 (60.0) | 1 (33.3) | |
| Pruritus (all grades) | 8 (6.6) | 3 (3.4) | 5 (15.2) | 0.034 |
| Grade 3–5 | 1 (12.5) | 1 (33.3) | 0 | |
| Dermatitis (all grades) | 7 (5.8) | 2 (2.3) | 5 (15.2) | 0.299 |
| Grade 3–5 | 0 | 0 | 0 | |
| Hepatitis (all grades) | 6 (5.0) | 4 (4.5) | 2 (6.1) | 0.664 |
| Grade 3–5 | 3 (50.0) | 3 (75.0) | 0 | |
| Diarrhea (all grades) | 6 (5.0) | 4 (4.5) | 2 (6.1) | 0.664 |
| Grade 3–5 | 1 (16.7) | 1 (25.0) | 0 | |
| Arthralgia (all grades) | 4 (3.3) | 2 (2.3) | 2 (6.1) | 0.299 |
| Grade 3–5 | 0 | 0 | 0 | |
| Hyperthyroidism (all grades) | 3 (2.5) | 2 (2.3) | 1 (3.0) | NA |
| Grade 3–5 | 0 | 0 | 0 | |
| Myocarditis (all grades) | 2 (1.7) | 2 (2.3) | 0 | NA |
| Grade 3–5 | 2 (100.0) | 2 (100.0) | 0 | |
| Dry skin (all grades) | 2 (1.7) | 1 (1.1) | 1 (3.0) | 0.473 |
| Grade 3–5 | 0 | 0 | 0 | |
| Hypercalcemia (all grades) | 2 (1.7) | 1 (1.1) | 1 (3.0) | 0.473 |
| Grade 3–5 | 0 | 0 | 0 | |
| Dyspepsia (all grades) | 1 (0.8) | 1 (1.1) | 0 | NA |
| Grade 3–5 | 0 | 0 | 0 | |
| Hypophysitis (all grades) | 1 (0.8) | 1 (1.1) | 0 | NA |
| Grade 3–5 | 0 | 0 | 0 | |
| Adrenal insufficiency (all grades) | 1 (0.8) | 1 (1.1) | 0 | NA |
| Grade 3–5 | 0 | 0 | 0 | |
| Hyponatremia (all grades) | 1 (0.8) | 1 (1.1) | 0 | NA |
| Grade 3–5 | 0 | 0 | 0 |
IO, immunotherapy; NA, not available.